文献速递临床试验与 GCP流行病学与生物统计真实世界研究与卫生经济

百万心脏模型对心肌梗死、卒中和医疗保险支出的影响:一项随机临床试验

Effects of the Million Hearts Model on Myocardial Infarctions, Strokes, and Medicare Spending: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2023-01-01

该实用性整群随机试验于2017至2021年纳入美国342家自愿参与的机构,评估百万心脏模型对无心肌梗死或卒中史且心血管病风险高或中等(10年预测概率≥15%)的医疗保险按服务收费受益人的影响。干预组5年内首次心血管病事件概率较对照组低0.3个百分点(HR 0.97,90%CI 0.93-1.00,P=0.09),首次心血管病事件与心血管病死亡复合终点低0.4个百分点(HR 0.96,90%CI 0.93-0.99,P=0.02),医疗保险支出两组相似。

要点

  • 百万心脏模型付费鼓励机构评估并降低心血管病风险,可减少首次心肌梗死和卒中。
  • 干预组5年首次心血管病事件概率较对照组低0.3个百分点,未达统计学显著(P=0.09)。
  • 干预组5年首次心血管病事件与心血管病死亡复合终点概率较对照组低0.4个百分点(P=0.02)。

核心结论

  • 百万心脏模型鼓励并付费支持心血管病风险评估与降低,减少了首次心肌梗死和卒中;结果支持使用风险评分进行心血管病一级预防的指南。

研究设计与样本

  • 实用性整群随机试验,2017至2021年运行,机构被分配至模型干预组或标准照护对照组。
  • 随机化机构包括516家美国初级保健和专科诊所、健康中心和医院门诊部,均为自愿参与。
  • 其中342家机构将患者纳入研究人群,纳入2017至2018年无既往心肌梗死或卒中且心血管病风险高或中等(10年预测心肌梗死或卒中概率即心血管病风险评分≥15%)的40至79岁医疗保险按服务收费受益人。

主要发现

  • 干预组高危及中危受益人(n=130578)与对照组受益人(n=88286)在年龄(中位72-73岁)、性别(58%-59%为男性)、种族(7%-8%为黑人)和基线心血管病风险评分(中位24%)方面相似。
  • 干预组5年内首次心血管病事件概率较对照组低0.3个百分点(相对效应3.3%;校正HR 0.97,90%CI 0.93-1.00;P=0.09)。
  • 干预组5年首次心血管病事件与心血管病死亡复合终点概率较对照组低0.4个百分点(相对效应4.2%;HR 0.96,90%CI 0.93-0.99;P=0.02)。
  • 心血管病事件的医疗保险支出两组相似(效应估计为每受益人每月-1.83美元,90%CI -3.97至-0.30;P=0.16)。
  • 包含模型付款的总医疗保险支出两组相似(效应估计为每受益人每月2.11美元,90%CI -16.66至20.89;P=0.85)。

关键数值与推荐

  • 模型机构同意执行符合指南的照护,包括对高危患者进行常规心血管病风险评估和心血管照护管理。
  • 美国医疗保险和医疗补助服务中心向机构付费,为医疗保险按服务收费受益人计算心血管病风险评分。
  • 美国医疗保险和医疗补助服务中心进一步奖励机构降低高危受益人(心血管病风险评分≥30%)的风险。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The Million Hearts Model paid health care organizations to assess and reduce cardiovascular disease (CVD) risk. Model effects on long-term outcomes are unknown. OBJECTIVE: To estimate model effects on first-time myocardial infarctions (MIs) and strokes and Medicare spending over a period up to 5 years. DESIGN, SETTING, AND PARTICIPANTS: This pragmatic cluster-randomized trial ran from 2017 to 2021, with organizations assigned to a model intervention group or standard care control group. Randomized organizations included 516 US-based primary care and specialty practices, health centers, and hospital-based outpatient clinics participating voluntarily. Of these organizations, 342 entered patients into the study population, which included Medicare fee-for-service beneficiaries aged 40 to 79 years with no previous MI or stroke and with high or medium CVD risk (a 10-year predicted probability of MI or stroke [ie, CVD risk score] ≥15%) in 2017-2018. INTERVENTION: Organizations agreed to perform guideline-concordant care, including routine CVD risk assessment and cardiovascular care management for high-risk patients. The Centers for Medicare & Medicaid Services paid organizations to calculate CVD risk scores for Medicare fee-for-service beneficiaries. CMS further rewarded organizations for reducing risk among high-risk beneficiaries (CVD risk score ≥30%). MAIN OUTCOMES AND MEASURES: Outcomes included first-time CVD events (MIs, strokes, and transient ischemic attacks) identified in Medicare claims, combined first-time CVD events from claims and CVD deaths (coronary heart disease or cerebrovascular disease deaths) identified using the National Death Index, and Medicare Parts A and B spending for CVD events and overall. Outcomes were measured through 2021. RESULTS: High- and medium-risk model intervention beneficiaries (n = 130 578) and standard care control beneficiaries (n = 88 286) were similar in age (median age, 72-73 y), sex (58%-59% men), race (7%-8% Black), and baseline CVD risk score (median, 24%). The probability of a first-time CVD event within 5 years was 0.3 percentage points lower for intervention beneficiaries than control beneficiaries (3.3% relative effect; adjusted hazard ratio [HR], 0.97 [90% CI, 0.93-1.00]; P = .09). The 5-year probability of combined first-time CVD events and CVD deaths was 0.4 percentage points lower in the intervention group (4.2% relative effect; HR, 0.96 [90% CI, 0.93-0.99]; P = .02). Medicare spending for CVD events was similar between the groups (effect estimate, -$1.83 per beneficiary per month [90% CI, -$3.97 to -$0.30]; P = .16), as was overall Medicare spending including model payments (effect estimate, $2.11 per beneficiary per month [90% CI, -$16.66 to $20.89]; P = .85). CONCLUSIONS AND RELEVANCE: The Million Hearts Model, which encouraged and paid for CVD risk assessment and reduction, reduced first-time MIs and strokes. Results support guidelines to use risk scores for CVD primary prevention. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04047147.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Blue L, Kranker K, Markovitz AR, et al. Effects of the Million Hearts Model on Myocardial Infarctions, Strokes, and Medicare Spending: A Randomized Clinical Trial. JAMA. 2023. PMID: 37847273. doi:10.1001/jama.2023.19597

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。